Berkshire Keeps Buying as Bears Retreat and the Street Turns Negative

Short positioning has eased since last week, even as the broader bearish narrative on LEN intensifies. Short interest of free float has dropped from a midweek peak above 11% to 9.3%, with week-on-week short interest falling 3.2% in line with the price decline. Borrow conditions are loose: availability has widened back to 330%, meaning roughly three shares are available in the lending pool for every one already borrowed. Cost to borrow is 0.43%, down on the week. The ORTEX short score sits at 61.4, elevated but off its intra-week high of 69.7 reached on October 7, suggesting some short-covering followed the sharpest move lower. Options positioning has flipped from defensively elevated earlier in the week. The put/call ratio is now 1.01, back below its 20-day mean of 1.07 and well off the 1.28 readings from earlier in October, so the options market has turned less hedged as the week has progressed.

The Street has turned decidedly negative. Morgan Stanley initiated coverage at Underweight with a $65 target on October 1. Melius Research followed with a Sell and a $72 target on October 6. Wells Fargo maintained Equal-Weight but cut its target from $80 to $75 on October 7. Multiple firms, including RBC, Barclays, Evercore ISI and Keefe Bruyette, lowered targets in the $69 to $85 range after the September earnings print. The mean analyst target is $77.87, only marginally above the current price of $74.92, and the factor scores reflect the damage: EPS momentum ranks in the 4th percentile on a 30-day view and the 13th on a 90-day view. Analyst recommendation divergence ranks in just the 2nd percentile, meaning the consensus is more uniformly negative than almost any stock in the universe. The bear case is concrete: F3Q26 EPS of $1.19 missed estimates, orders fell 9% year-on-year, average closing prices dropped to $372,000, and FY26 delivery guidance was cut to 82,000 to 83,000 homes. Price-to-book has compressed to 0.86 over the past 30 days, down from above 0.96 a month ago.

ORTEX's index rebalance radar adds a mechanical wrinkle for December. ORTEX puts a 75% probability on LEN being added to the CRSP US Small index at the December 2026 quarterly review, which would require buying of roughly $191 million by index trackers. The rank date is December 4, with a trade date of December 22. The price that flips the index rule in LEN's favour is $89.09, about 19% above where the stock trades today. At the same review, ORTEX forecasts a 75% chance of a share decrease in both the CRSP US Large and CRSP US Mid indices, implying $35 million and $117 million of selling respectively. These are forecasts, not announcements, and no index provider has confirmed any change.

The homebuilding peer group was broadly weaker on the week. KBH fell 7%, GRBK dropped 7.9%, and MTH lost 7.3%. DHI held up better, down less than 1%. LEN's 3.2% weekly decline sits near the middle of the group, which suggests the sector rather than a company-specific catalyst drove most of the move.

The key dates to watch from here are the December 4 CRSP rank date, which sets the index rebalance outcome, and the December 16 earnings call, where the trajectory of order ASPs and the FY27 delivery framework will determine whether the discount Berkshire is paying looks prescient or premature.